Letrazole Femara Letrozole 2.5mg 100pcs oral steroids tablets

Description

Letrozole Femara Type II Aromatase Inhibitor Research

Molecular Data

• CAS Number: 112809-51-5
• Molecular Formula: C17H11N5
• Molecular Weight: 285.31 g/mol
• Purity: >99.0% via HPLC-UV
• Appearance: Fine white to yellowish crystalline powder

Pharmacodynamics

The biochemical activity of Letrozole is defined by its competitive, reversible binding to the heme group of the cytochrome P450 enzyme aromatase (CYP19A1). Initially, the triazole ring of the molecule coordinates with the iron atom within the enzyme’s active site. This defines the first semantic triple: [Letrozole binds the CYP19A1 heme group]. Secondly, this specific interaction mechanically blocks the conversion of androstenedione and testosterone into estrone and estradiol. This establishes the second triple: [Aromatase inhibition halts estrogen biosynthesis]. Finally, the resulting estrogen deficit alters the hypothalamic-pituitary-gonadal axis feedback loop, often stimulating endogenous gonadotropin release. This forms the third triple: [Estrogen reduction triggers gonadotropin secretion]. Quantitatively, Letrozole possesses a systemic half-life of approximately 48 hours ($t_{1/2}=48.0pm4.0$h) in research models, providing sustained enzyme suppression. In comparative studies, Letrozole is distinguished from Anastrozole Arimidex by its significantly higher binding affinity and greater potency; it can suppress serum estrogen levels by up to 98%, whereas Anastrozole typically achieves 85-90% suppression.

About This Compound

Letrozole, frequently referenced as Femara, is a highly potent, reversible, non-steroidal aromatase inhibitor (AI). This signaling molecule serves as a primary research benchmark for investigating the profound suppression of estrogen biosynthesis. [Letrozole inhibits the aromatase enzyme]. It provides a high-fidelity model for evaluating endocrine modulation and the precise control of the androgen-to-estrogen ratio.

Experimental Outcomes

• Profound Estrogen Suppression: Users in research models report near-total elimination of circulating estradiol, significantly altering systemic fluid retention.
• Glandular Tissue Resolution: Published research indicates high efficacy in reversing or mitigating estrogen-receptor-mediated tissue anomalies, such as gynecomastia.
• Endogenous Testosterone Rebound: Based on community feedback, research models show a compensatory increase in LH, FSH, and total testosterone due to the disrupted negative feedback loop.
• Lean Tissue Hardening: Multiple research groups note a distinct hardening effect on skeletal muscle, primarily driven by the extreme reduction in subcutaneous water.
• Metabolic Shift: Research models have observed alterations in lipid metabolism and bone mineral density during prolonged administration phases.

In Brief:
Letrozole Femara represents an exceptionally potent research tool for investigating extreme aromatase inhibition and the molecular pathways of complete estrogen suppression.

Frequently Asked Questions

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before use.